Knopp Biosciences is a drug discovery and development company focused on delivering breakthrough treatments in neurological disorders through innovation, experience and partnership. Knopp’s lead compound, KNS-760704, is currently in clinical development for amyotrophic lateral sclerosis, with additional indications under investigation.
Employees: 11-50
Total raised: $17.5M
Founded date: 2004
Investors 1
| Date | Name | Website |
| - | Saturn Par... | saturnpart... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.12.2014 | - | $5M | - |
| 25.09.2009 | - | $12.5M | - |
Mentions in press and media 17
| Date | Title | Description |
| 15.12.2014 | Knopp Biosciences raises $5M, pivots flailing ALS drug to target new indication | A lot of hopes were pinned on using dexpramipexole to treat those with ALS. But it the small molecule drug, thought to maintain mitochondrial function, flopped in Biogen Idecs Phase 3 trials last year: Though fast-tracked in 2009 for the i... |
| 14.08.2013 | Foundations team up to fund translational research on mitochondrial diseases, Alzheimer’s | Pittsburgh’s Knopp Biosciences, Silicon Valley’s Edison Pharmaceuticals and Khondrion in The Netherlands are a few companies that are developing drugs for these conditions. Areas of priority for the grants include discovery and development ... |
| 12.08.2013 | Knopp Biosciences Partners with MMS Holdings Inc. to Manage Pharmacovigilance Services | Canton, MI (August 1, 2013) – MMS Holdings Inc. today announced that it has been selected to partner with Knopp Biosciences to provide best-in-class pharmacovigilance services in support of their compound, dexpramipexole. The MMS Holdings t... |
| 17.06.2013 | Prize4Life and Knopp Neurosciences Announce Donation of EMPOWER Phase 3 Data to PRO-ACT Database | CAMBRIDGE, MA. & PITTSBURGH, PA — Prize4Life and Knopp Neurosciences Inc. today announced an agreement under which Knopp will donate data from one of the largest clinical trials ever conducted in amyotrophic lateral sclerosis (ALS) to t... |
| 14.11.2012 | Drug developer advancing Phase 2 drug for Lou Gehrig’s disease raises $15M | Product: Its lead product is dexpramipexole for amyotrophic lateral sclerosis or Lou Gehrig’s disease and is being developed with Biogen. It is designed to protect stressed neurons and other cell types from dying, according to its website. ... |
| 13.07.2012 | Biotechnology firm raising $30M to advance treatment for Parkinson’s, neurodegenerative disease | Since it forged a licensing deal with Biogen in 2010 for its ALS drug dexpramipexole, Knopp has doubled its research and development facilities and increased its staff to 33. In May, it hired Dr. Steven Boyd, formerly of Array BioPharma and... |
| 06.06.2011 | LaunchCyte raises $1.1M to commercialize biotech discoveries | The latest funding, $1.055 million, comes in the form of equity and is anticipated to be part of a $1.575 million fundraise. It was sourced from six investors, according to the regulatory document. LaunchCyte’s portfolio companies include I... |
| 22.06.2010 | LaunchCyte raises $1 million | By Brandon Glenn Biotechnology commercialization company LaunchCyte LLC raised nearly $1 million in debt, options and warrants, according to a filing with the Securities & Exchange Commission. The company pulled in $927,000 of the nearl... |
| 21.06.2010 | Biotech commercialization firm LaunchCyte raises nearly $1M | It’s unclear what plans LaunchCyte has for its latest round of funding. CEO Tom Petzinger didn’t return a call. LaunchCyte’s portfolio companies include Immunetrics Inc., which develops software for clinical trials, Celsense Inc., which off... |
| 25.09.2009 | Pittsburgh’s Knopp NeuroSciences raising $12.5 million for ALS drug | Promoted Covid-19’s terrible toll on diabetes patients. What can be done? The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
Show more